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West Nile (WN) virus was first isolated and identified
from the blood of a febrile woman in Uganda in 1937 (1); fever
was her only known symptom. In the early 1950s, several
reports from outbreaks in Israel were the first to detail the
clinical characteristic of this illness; the clinical picture that
emerged was that of a benign febrile disease in young adults
(2,3). In a later outbreak from Israel in 1957, a linkage between
WN virus infection and severe central nervous system (CNS)
disease was first noted, and a correlation between the age of
patients and severity of disease was established (4).
In the last decade, two outbreaks gained attention: the
first from Romania in 1996, where a high percentage of CNS
involvement was noted, and the second from New York in
1999, in which several cases of flaccid paralysis were
described (5,6). The outbreak in New York was the first time
WN fever was reported in the Western Hemisphere (7).
From August to October 2000, 417 laboratory-confirmed
WN fever cases occurred in Israel; 326 were hospitalized
cases. We collected clinical data on 233 of the hospitalized
population from 12 different hospitals throughout the country.
We report the clinical characteristics of these patients.
Methods
Study Population
A case of WN fever was defined as illness in a patient with
a clinical picture consistent with WN fever and with anti-WN
virus immunoglobulin (Ig) M antibodies detected in either a
serum or cerebrospinal fluid (CSF) specimen. The study
populat:ion was persons who were hospitalized and diagnosed
from August 1, 2000, to October 31, 2000. Patients with
headache and abnormal CSF findings, with no confusion or
change in level of consciousness (i.e., drowsiness to coma),
were diagnosed as having meningitis. Patients with an
altered level of consciousness, confusion, or focal neurologic
signs were diagnosed as having encephalitis, regardless of
CSF findings. Patients with severe weakness of limbs or
flaccid paralysis were diagnosed as having myelitis. Patients
with fever and no CNS symptoms were diagnosed as having
febrile disease.
A total of 325 WN fever patients were hospitalized in 20
hospitals. Data were obtained from 12 (60%) of the hospitals
and 233 (71%) of the 326 patients. The geographic location of
hospitals that participated in the study was similar to that of
nonparticipating hospitals. No exclusion was made based on
patient characteristics.
Demographic, epidemiologic, and clinical data were
collected by infectious disease specialists in each hospital,
using a structured questionnaire. Information was obtained
by interviewing the patients and reviewing medical records or
by reviewing the charts in cases in which the diagnosis was
confirmed after the discharge of the patients.
Serologic Testing
Serologic diagnosis of WN virus infection was based on an
IgM-capture enzyme-linked immunosorbent assay (ELISA),
performed in serum or CSF samples. The assay, which was
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West Nile (WN) virus is endemic in Israel. The last reported outbreak had
occurred in 1981. From August to October 2000, a large-scale epidemic of WN
fever occurred in Israel; 417 cases were confirmed, with 326 hospitalizations.
The main clinical presentations were encephalitis (57.9%), febrile disease
(24.4%), and meningitis (15.9%). Within the study group, 33 (14.1%)
hospitalized patients died. Mortality was higher among patients >70 years
(29.3%). On multivariate regressional analysis, independent predictors of death
were age >70 years (odds ratio [OR] 7.7), change in level of consciousness (OR
9.0), and anemia (OR 2.7). In contrast to prior reports, WN fever appears to be
a severe illness with high rate of central nervous system involvement and a
particularly grim outcome in the elderly.676 Emerging Infectious Diseases Vol. 7, No. 4, July–August 2001
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developed in the Central Virology Laboratory during 1999
and 2000, includes the following steps: coating of ELISA plate
with goat anti-human IgM  and stepwise incubation with the
patient’s serum (diluted 1:100 and 1:2,000) or CSF (diluted
1:10 and 1:100 for CSF); WN virus antigen was prepared from
Vero cells infected with an Israeli gull isolate from 1999;
mouse anti-flavivirus monoclonal antibodies (TropBio,
Australia); horseradish peroxidase conjugated goat anti-
mouse antibody (Jackson Imunoresearch Laboratories, West
Grove, PA, USA), and o-phenylenediamine as substrate.
Cross-reaction with other flaviviruses was not thoroughly
evaluated; however, no other known endemic cross-reacting
Flavivirus infects humans in Israel.
Statistical Analysis
The Fisher exact test was applied to compare differences
between diagnosis by age: <70 years or >70 years. A two-step
process was used to determine which of the proposed risk
factors were independently associated with death. A bivariate
logistic regression analysis was used to determine the asso-
ciation of individual risk factors with death. Subsequently, a
multivariate logistic regression analyses was performed, with
a forward elimination model. Variables for this analysis were
selected if they fulfilled the following criteria: 1) level of
significance of p<0.15 in the bivariate analysis; 2) data on
variables were available in >92% of patients; and 3) variables
on which sufficient information was available and occurred in
more than 10% of the cases. Data were analyzed with the SAS
program (version 6.12).
Results
The age distribution of the 233 patients for whom data
were available is delineated in Figure 1. The mean age of the
patients was 59 (±23.5 standard deviations) years old. The
median age was 65 years (range 3 to 95 years). A large
percentage (79.8%) of patients had one or more coexisting
illnesses or conditions, including hypertension, diabetes
mellitus, ischemic heart disease, renal failure, obstructive
lung disease, and immunodeficiency such as organ
transplantation, malignancy, and chemotherapy.
Three main clinical presentations were prominent in
hospitalized patients with WN fever: encephalitis (57.9%),
febrile illness (24.4%), and meningitis (15.9%). Compared
with persons <70 years of age (n=134), older persons (n=99)
were more likely to have encephalitis (80% vs. 41%) and were
less likely to have febrile illness (18% vs. 30%) or meningitis
(1% vs. 27%) (p<0.00001).
Table 1 presents the symptoms and signs during the
disease course. Fever (>38°C) was almost universally present.
Sixty percent of the patients had fever above 39°C and 20%
had fever above 40°C. Headache, myalgia, chills, and rash
were common, as were gastrointestinal complains such as
abdominal pain and diarrhea. Lymphadenopathy was
infrequent (Table 1).
Symptoms and signs that suggested CNS involvement
were common: nuchal rigidity was present in 28.7%,
confusion in 39.5%, and change in level of consciousness in
46.8%; 17.7% of the hospitalized patients deteriorated into
coma. Thirty-seven patients received enteral ribavirin as an
experimental therapy
Lumbar puncture was performed in 153 patients (65.6%).
The findings were characteristic of viral infection and
demonstrated mild leukocytosis (median 77 leukocytes/mm3;
range 0 to 1,750), high protein (median 85 mg/dL; range 18
to 1,900), and normal glucose (median 67 mg/dL; range 2.8
to 197).
Brain computerized tomography (CT) scan was per-
formed for 105 patients. The findings were interpreted as
normal in 62 patients (58%). Abnormal findings included old
infarcts (18%), cortical atrophy (13%), meningioma (4%), old
hemorrhages (2%), and multiple brain metastasis (1%). None
of these findings were attributable to WN virus infection.
Electroencephalogram (EEG), performed in 43 patients, was
consistent with encephalitis in 34 (79%). No specific pattern
for WN virus infection was found.
Laboratory results are depicted in Table 2. Anemia was
documented in 41.1% of the patients. Leukocytosis,
thrombocytopenia, and leukopenia were documented in
35.9%, 14.9%, and 8.6% of patients, respectively. Liver
function tests were mildly impaired in 20% of patients. Mild
electrolyte abnormalities and elevated urea were noted.
Anti-WN virus IgM antibodies were detected in serum
(143 cases), CSF (27 cases) or both (63 cases). Of note, many of
these samples were obtained on the first week of symptoms
(83 of serum samples and 50 of CSF samples) and were found
to be already positive at that time (Figure 2).
Figure 1. Age distribution of 233 hospitalized patients with West Nile
fever. Fatal cases are shown in hatched bars.
Table 1. Signs and symptoms of 233 hospitalized patients with West
Nile fever
Symptoms and signs No. (%)
Fever >38°C 229 (98.3%)
Headache 135 (57.9%)
Change in level of consciousness 109 (46.8%)
Confused state 92 (39.5%)
Vomiting 73 (31.3%)
Nuchal rigidity 67 (28.7%)
Rash 51 (21.8%)
GI symptomsa 43 (18.5%)
Coma 39 (16.7%)
Myalgia 36 (15.4%)
Focal neurologic signs 22   (9.4%)
Lymphadenopathy 10   (4.3%)
aAbdominal pain, diarrhea; GI = gastrointestinal.677 Vol. 7, No. 4, July–August 2001 Emerging Infectious Diseases
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Thirty-three patients (14.1%) in the study group died
during hospitalization. Their median age was 80 years (range
54 to 95). The mortality rate among patients >70 years
increased to 29.3%. All fatal cases but one were >68 years. A
54-year-old woman with myasthenia gravis, treated with
azathioprine, was the youngest to die from WN virus
encephalitis.
We tried to identify clinical and laboratory variables
associated with death. By bivariate logistic regression
analysis, age >70 years, headache, confusion, changes in level
of consciousness, anemia on admission, and ribavirin therapy
were found to be associated with death. Lack of a coexisting
condition was protective (p<0.05). No single coexisting
condition was found to be a significant predictor of death.
Sixteen patients were immunocompromised because of
heterogeneous conditions, i.e., organ transplantation,
malignancy, and chemotherapy. Only four of these patients
were  >70 years. Mortality rate was higher among the
immunocompromised (5/16) than among those not immuno-
compromised (28/217); p=0.052, odds ratio [OR] 3.1, 95%
confidence intervals 1.0-9.5).
Multivariate logistic regression analysis was performed
with all variables in Table 3. Three variables were
independently correlated with death: age >70 years (OR 7.7,
p= 0.0004), change in level of consciousness (OR 9.0,
p=0.0007), and anemia at presentation (OR 2.7, p=0.028).
Discussion
In this report we summarized the clinical characteristics
of 233 hospitalized patients during a large-scale outbreak of
WN fever in Israel. Our data indicated that WN fever was a
severe disease with significant CNS involvement and high
mortality (14.1% death rate in the study group). Furthermore,
a clear correlation between age and increased severity and
death was noted. Eighty percent of hospitalized patients >70
years of age had encephalitis, and deaths in this age group
rose to 29.3%. Such findings raise the question of whether old
age was a risk factor in itself or whether coexisting conditions
associated with advanced age account for the observed
increased risk. Importantly, in the bivariate regression
analysis no single coexisting condition or illness was
correlated with death. Moreover, in the multivariate
regression analysis, age >70 years was an independent risk
factor. These findings agree with the results of a case-control
study in Romania in which no correlation between an underlying
medical condition and meningoencephalitis was found (8).
Immunosuppressive therapy, which nearly reached
statistical significance, may be the exception to this finding.
Notably, the only fatality in a patient <68 years occurred in a
woman treated by immunosuppressive therapy.
The reasons for the high death rates observed in the
present epidemic are not clear. Mortality was higher than
Table 2. Laboratory abnormalities, on admission, in hospitalized
patients with West Nile fever
Laboratory results No. (%)
Hb <12 g/dL in F Hb <13.5 g/dL in M 91/221 (41.1)
WBC <4.8 K/µL 19/220   (8.6)
WBC >10.8 K/µL 79/220 (35.9)
PLT <140 K/µL 33/221 (14.9)
SGOT >37 U/L 36/200 (18)
Alkaline phosphatase >117 U/L 41/197 (20.8)
Na <135 mEq/L 72/216 (33.3)
K <3.5 mEq/L 29/215 (13.5)
Urea >50 mg/dL 39/213 (18.3)
Abbreviations used in this table: n = abnormal results/available results; WBC =
leukocyte count;  PLT = platelets;  SGOT = serum glutamic oxalacetic
transaminase.
Figure 2. Number of positive blood samples for immunoglobulin (Ig)
M serology and time from beginning of symptoms. Blood samples
were obtained from the patients upon initial suspicion of the
diagnosis of West Nile fever. Bars represent the numbers of persons
with positive serology at a given time after the onset of symptoms.
Table 3. Variables entered into the multivariate regression analysis
Variables Alive  200 (%) Dead  33 (%) O.R. (95% CI) p value*
Age >70 70 (35.0) 29 (87.9) 13.5 (4.5-39.8) 0.0001
No coexisting condition or illness 53 (26.5) 2   (6) 0.2   (0.1-0.9) 0.03
Diabetes mellitus 31 (15.5) 9 (27.3) 2.0   (0.9-4.8) 0.1
Ischemic heart disease 29 (14.5) 9 (27.3) 2.2   (0.9-5.2) 0.07
Temp (mean +/-SD) 39.1 +/-0.7 39.3 +/-0.64 1.6   (0.9-2.7) 0.08
Headache 123 (61.5) 12 (36.4) 0.4   (0.2-0.9) 0.02
Confusion 68 (34.0) 24 (72.7) 5.2 (2.2-11.7) 0.0001
Change in level of consciousness 80 (40) 29 (87.9) 15.3 (4.5-51.9) 0.0001
Hb<12 g/dL in F Hb<13.5 g/dL in M 72 (36) 19 (57.5) 3.0   (1.4-6.7) 0.006
PLT<140 K/mL 25 (12.5) 8 (24.2) 2.1   (0.8-4.6) 0.1
Ribavirin therapy 22 (11.0) 15 (45.4) 6.7 (3.0-15.2) 0.0001
aOnly factors included were those that were significant with p<0.15 by bivariate regression analysis, were available in more than 92% of the cases, and occurred
in more than 10% of the cases.
SD = standard deviation; OR = odds ratio; CI = confidence intervals; Hb = hemoglobin;  PLT =  platelets.678 Emerging Infectious Diseases Vol. 7, No. 4, July–August 2001
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that described in the outbreak in Romania in 1996 (14.3% vs.
4.3%, respectively), despite the fact that a high percentage of
CNS involvement (89%) was noted in Romania as well (9).
High background immunity may account for lower morbidity
and deaths. However, the outbreak in Romania was the first
reported from that area, and therefore occurred in a
population with low background immunity. In fact, the
seroprevalence after the outbreak in Romania was reported to
be 4.1% (5), compared with seroprevalence of 18.6% in a
healthy adult population in Israel in the 1980s (10). Thus,
background immunity of the population could not explain the
difference in death rates.
Introduction of a new, more virulent strain of WN virus is
another possible explanation for the high death rate. Studies
in North America support this hypothesis. Mortality during
the outbreak in New York (11.4%) was closer to that from
Israel. Viral isolates from the outbreak in New York showed a
99.8% genomic similarity to WN virus strain from the brain of
a dead goose in Israel in 1998, as well as a fatal human case
from Israel in 1999 (11,12). In addition, avian deaths caused
by WN viral infection were reported only from North America
and Israel, a phenomenon that had not been reported
previously. Taken together, these findings suggest that a new
strain of WN virus identified in the United States and Israel
may be responsible for the higher death rates in these countries.
The signs and symptoms of the disease are not specific,
and their percentages seem to differ considerably in the
outbreaks reported. Data from confirmed cases of outbreaks
in Israel in the early 1950s indicate that fever, headache, and
lymphadenopathy were almost universal findings (80% to
100%), with rash in 50% and gastrointestinal complaints in
20% to 30% (2). The study from Romania showed high
prevalence of fever and headache but noted only 5% rash, 11%
gastrointestinal symptoms, and 2.4% lymphadenopathy (9).
In our series, fever, headache, and change in level of
consciousness were the most frequent findings; rash was less
frequent (28.1%). Differences in study population and case
definitions, as well as methods of data collection, may account
for such discrepancies. Alternatively, the variation in clinical
manifestations may have occurred because of differences
between viral strains.
Laboratory results were mostly normal. The mild
changes in electrolyte and urea could be attributed to changes
in fluid balance in patients with vomiting and diarrhea.
Anemia on admission was reported in a high proportion of our
patients and was found to be independently associated with
fatal outcome. Anemia has not been reported as an important
laboratory abnormality in other flaviviral infections (13);
with the limited data available, determining whether it was
caused by the WN fever or whether it antedated the infection
could not be assessed.
A large number of patients underwent brain CT and EEG
examinations. CT showed abnormalities in 40% of the
patients, but none were specific to the disease and reflected
mostly the age of the patients. These results agree with
published findings from New York (6).
Generally, the signs, symptoms, laboratory findings, and
imaging results in WN fever are nonspecific. Similar to
reports from Romania, we found that a high number of blood
and CSF specimens obtained during the first week of
symptoms were already positive by IgM serology (14).
Therefore, this specific test is important for timely diagnosis.
Our study had some limitations. Because the patient
population was distributed in multiple hospitals, the physical
examination, clinical assessment, and chart review were
performed by different physicians. This may have resulted in
some skewing of the percentages of the different signs and
symptoms attributed to the disease.
Despite a detailed analysis of the clinical manifestations,
signs, symptoms, and laboratory results of patients with WN
fever, no findings are diagnostic. A febrile illness with
neurologic manifestations in elderly patients hospitalized in
the summer or fall should raise the possibility of WN fever
and prompt a work-up to establish the diagnosis.
Finally, this study identified a specific group with
increased risk for death from WN fever. The elderly might be
a suitable target group for protective vaccines.
Dr. Chowers is an infectious disease specialist in Meir Medical
Center, Kfar Sava, Israel, which is affiliated with Tel Aviv University.
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